This product has a broad-spectrum antibacterial effect, especially high antibacterial activity against aerobic Gram-negative bacilli. It has good antibacterial activity in vitro against the following bacteria: most bacteria of the Enterobacteriaceae family, including Citrobacter, Enterobacter cloacae, Enterobacter aerogenes, Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, Vibrio, Yersinia, etc. It often has antibacterial activity against multi-drug resistant bacteria. It has high antibacterial activity against penicillin-resistant Neisseria gonorrhoeae, enzyme-producing Haemophilus influenzae and Moraxella. It has antibacterial activity against most strains of Pseudomonas such as Pseudomonas aeruginosa. This product has antibacterial activity against methicillin-sensitive Staphylococcus aureus, and only moderate antibacterial activity against Streptococcus pneumoniae, hemolytic Streptococcus and Enterococcus faecalis. It has good antimicrobial activity against Chlamydia trachomatis, Mycoplasma, Legionella, and also has antibacterial activity against Mycobacterium tuberculosis and atypical mycobacteria. Poor antibacterial activity against anaerobic bacteria. Ciprofloxacin is a bactericide that acts on the A subunit of bacterial DNA helicase, inhibiting DNA synthesis and replication, leading to bacterial death.

Inhibits bacterial protein synthesis and has antibacterial effects on Gram-positive bacteria and Chlamydia trachomatis

Erythromycin is a macrolide antibiotic whose mechanism of action is to inhibit bacterial protein synthesis. It has antibacterial effects on Gram-positive bacteria and Chlamydia trachomatis.

Erythromycin is a macrolide antibiotic whose mechanism of action is to inhibit bacterial protein synthesis. It has antibacterial effects on Gram-positive bacteria and Chlamydia trachomatis.

This product is a chloramphenicol antibiotic. It has a broad-spectrum antimicrobial effect in vitro, including aerobic Gram-negative and Gram-positive bacteria, anaerobes, Rickettsia, spirochetes and Chlamydia. It has bactericidal effects on the following bacteria: Haemophilus influenzae, Streptococcus pneumoniae and Neisseria meningitidis. It only has antibacterial effects on the following bacteria: Staphylococcus aureus, Streptococcus pyogenes, Streptococcus viridans, Group B hemolytic Streptococcus, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Salmonella typhi, Salmonella paratyphi, Shigella, Bacteroides fragilis and other anaerobic bacteria. The following bacteria are usually resistant to chloramphenicol: Pseudomonas aeruginosa, Acinetobacter, Enterobacter, Serratia marcescens, indole-positive Proteus, methicillin-resistant Staphylococcus and Enterococcus. This product is an antibacterial agent. Chloramphenicol is fat-soluble and enters bacterial cells by diffusion, and reversibly binds to the 50S subunit of the bacterial ribosome, which blocks the growth of the peptide chain (possibly due to the inhibition of the action of transpeptidase), thereby inhibiting the formation of the peptide chain and preventing protein synthesis.

Diclofenac sodium is a non-steroidal anti-inflammatory analgesic derived from phenylacetic acid. Its mechanism of action is to inhibit the activity of cyclooxygenase, thereby blocking the conversion of arachidonic acid to prostaglandins. At the same time, it can also promote the combination of arachidonic acid with triglycerides, reduce the concentration of free arachidonic acid in cells, and indirectly inhibit the synthesis of leukotrienes. Animal experiments have confirmed that prostaglandins are one of the mediators of intraocular inflammation, which can lead to blood-aqueous barrier collapse, vasodilation, increased vascular permeability, leukocyte chemotaxis, non-cholinergic mechanism pupil constriction, etc. Diclofenac sodium is a stronger non-steroidal anti-inflammatory drug. Its inhibitory effect on prostaglandin synthesis is stronger than that of aspirin and indomethacin. Diclofenac sodium eye drops have a strong inhibitory effect on the collapse of the blood-aqueous barrier caused by mechanical, chemical, biological and other stimuli. Clinical studies have shown that 0.1% diclofenac sodium can reduce the flare and cell count in the anterior chamber in the treatment of post-cataract surgery inflammation; it can relieve postoperative pain and photophobia in patients undergoing radial keratectomy or laser refractive keratectomy, and is better than placebo.

This product is a nucleoside antiviral drug that has a selective inhibitory effect on a variety of herpes viruses (HSV). After acyclovir enters HSV-infected cells, it binds to the specific thymidylate kinase encoded by the virus and is rapidly converted into acyclosine monophosphate, which is then converted into acyclosine diphosphate by the cell guanylate kinase, and then converted into acyclosine triphosphate by other cell enzymes, and competes with guanylate triphosphate to infect herpes simplex virus DNA polymerase, thereby inhibiting viral DNA synthesis. Acyclovir triphosphate is a strong viral DNA polymerase inhibitor, which has an inhibitory effect on the DNA polymerase of five human herpes viruses, namely HSV-1, HSV-2, VZV, CMZ and EBV, and has no effect on normal cells. Its antiviral efficacy is 160 times stronger than that of adenosine.